GHRP-6

GHRP-6 is a synthetic six-amino-acid peptide, one of the original growth hormone releasing peptides discovered in the 1980s, that stimulates the pituitary gland to release growth hormone through the ghrelin receptor. It is well known for strongly increasing hunger as a side effect of the same mechanism. GHRP-6 has never been developed into an approved medicine; it exists today mainly as an unapproved research chemical widely used off-label in bodybuilding and anti-aging communities, with dosing information drawn almost entirely from vendor sites and forums rather than clinical trials.

Research snapshot

Peptide category	Synthetic growth hormone releasing hexapeptide (ghrelin receptor agonist)
Primary research interest	Growth hormone release; historically important as an early research tool for the ghrelin/GH-secretagogue receptor pathway
Highest available evidence	Tier 4/5 — an important early laboratory and mechanistic research tool; not carried into drug development, so modern off-label use is supported mainly by community/vendor material
Human research available	Some early mechanistic human research exists from its discovery era; not developed through modern clinical trials for an approved indication
Development status	Not carried into drug development or marketing after its discovery-era research role
Regulatory status	Never approved as a drug in any major jurisdiction (US, EU, Japan); not legally sold as an approved drug or dietary supplement in the US; sold by research-chemical vendors as unregulated material

Technical identity

Primary name	GHRP-6 (Growth Hormone Releasing Peptide-6)
Alternative names	Growth hormone releasing hexapeptide
Peptide sequence	His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (commonly cited sequence; not independently re-verified against a primary source in this pass)
Amino-acid length	6 (hexapeptide, includes unnatural D-amino acids)
Molecular formula	Not independently re-verified in this pass
Molecular weight	Commonly cited around 873 g/mol; not independently re-verified in this pass
CAS Registry Number	Not independently re-verified in this pass
PubChem CID	Not independently re-verified in this pass
Peptide class	Growth hormone secretagogue (ghrelin receptor agonist family)
Primary biological target	Ghrelin receptor (GHS-R1a)
Developer or originator	Academic research (Cyril Bowers and colleagues), one of the earliest characterized GH secretagogue peptides, discovered in the 1980s
Development status	Not developed into an approved medicine; used as a research tool

What is GHRP-6?

GHRP-6 (growth hormone releasing peptide-6) is a lab-made hexapeptide — six amino acids, some of them unnatural, linked together — designed to make the pituitary gland secrete growth hormone. It was one of the earliest members of the growth hormone secretagogue family to be characterized, developed out of research led by Cyril Bowers and colleagues that began by modifying natural opioid peptide (met-enkephalin) structures in search of compounds that would release growth hormone rather than act as opioids. The compound was originally studied under the code name SKF-110679.

Early human research in the late 1980s and early 1990s (including work by Hartman and colleagues) demonstrated that GHRP-6 could stimulate GH secretion in healthy men, including with oral administration, though oral bioavailability is very low. GHRP-6 helped establish the entire concept that a peptide acting through a receptor separate from GHRH could reliably provoke GH release — a finding that eventually led to the discovery of ghrelin itself as the natural hormone acting on that same receptor.

Despite this important role in growth hormone secretagogue research, GHRP-6 itself was never carried through to drug approval. It is not sold as an approved medicine anywhere. Today “GHRP-6” is sold almost exclusively as an unregulated peptide through research-chemical vendors, and it has a substantial following in bodybuilding and self-experimentation communities, largely because of its pronounced appetite-stimulating effect alongside its GH-releasing action.

How does it work?

Plain-English explanation

GHRP-6 attaches to the same receptor that the body’s natural hunger hormone, ghrelin, uses. Activating that receptor in the pituitary gland causes a pulse of growth hormone to be released into the bloodstream. Because that receptor also drives appetite, GHRP-6 is known for producing a strong, fairly immediate increase in hunger — often described as one of its most noticeable effects.

Technical explanation

GHRP-6 is a growth hormone secretagogue receptor (GHSR-1a) agonist, acting as a synthetic ghrelin mimetic rather than working through the hypothalamic GHRH pathway. Activation at the pituitary somatotroph stimulates pulsatile GH release. Because GHRP-6 and GHRH act on separate receptors, combining a GHRP-family peptide with a GHRH analog produces a synergistic, larger GH pulse than either alone, a relationship that has been repeatedly demonstrated in human pharmacodynamic studies of the class. Oral bioavailability of GHRP-6 is reported as under 1%, and its elimination half-life after parenteral administration is short (on the order of a few hours), which is part of why community protocols favor multiple daily injections rather than once-daily dosing.

Potential benefits and research applications

Growth hormone release (human pharmacology evidence)

What is being investigated: GHRP-6’s ability to provoke an acute pulse of GH secretion. How the effect might occur: direct GHSR agonism at the pituitary. Evidence: this has been shown repeatedly in small human pharmacology studies dating back to the late 1980s and early 1990s, including studies of oral and injected administration in healthy men. Strength: the acute GH-releasing effect is well established for GHRP-6 specifically. Limitation: most published human studies used single or short-term dosing designed to characterize the GH response, not the daily, months-long self-administration regimens described in community use today.

Appetite stimulation (human and mechanistic evidence)

What is being investigated: the orexigenic (hunger-increasing) effect of GHSR activation, which has been explored in the broader ghrelin-agonist literature for conditions involving poor appetite or wasting. How the effect might occur: through the same GHSR pathway responsible for ghrelin’s natural hunger signal. Evidence: appetite stimulation is a consistently and strongly reported effect of GHRP-6 specifically, both in early human pharmacology work and in community reports. Strength: well-documented mechanistically and observationally. Limitation: GHRP-6 has not been developed or approved for any appetite-related medical indication.

Muscle gain, recovery, and fat loss claims (community-reported, largely unestablished)

What is being investigated: whether repeated GHRP-6 use, by raising GH and downstream IGF-1, meaningfully improves body composition or recovery in healthy or athletic adults. How the effect might occur: theoretically via sustained elevation of GH/IGF-1 signaling. Evidence: these claims are almost entirely anecdotal, reported in bodybuilding forums and vendor marketing rather than in controlled trials of GHRP-6 for these outcomes. Strength: has not been established in controlled human research. Limitation: no peer-reviewed trial has evaluated GHRP-6 for body-composition or athletic-performance outcomes in healthy adults.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Amounts studied in human research

Early pharmacology studies (for example, Hartman et al., studying GH secretion in normal men) tested GHRP-6 administered orally and parenterally in healthy male volunteers, and a pharmacokinetic study in nine healthy men has been described in the literature reporting an oral bioavailability under 1% and an elimination half-life of roughly 2.5 hours. This session could not independently verify the specific milligram/microgram doses used in each of these individual published studies from primary sources; the exact numeric doses tested in the foundational human research should be confirmed against the original papers rather than assumed from secondary summaries.

Amounts studied in animal research

Not consistently reported. GHRP-6 has been used in various animal studies characterizing the GHSR pathway and orexigenic signaling, but a consolidated, independently verifiable set of GHRP-6-specific animal dosing figures was not identified in this research pass.

Practitioner and community-reported protocols

Peptide vendor sites and bodybuilding/anti-aging forums very consistently describe GHRP-6 doses of roughly 100 to 300 micrograms per injection, given subcutaneously two to three times per day (commonly on waking, around training, and before bed), frequently paired with a GHRH-type peptide such as CJC-1295 or sermorelin, similar to how GHRP-2 is discussed in the same communities. This range is widely repeated online but its original source could not be verified, and it does not appear to trace to a specific published clinical protocol. Community sources also consistently note that GHRP-6’s hunger-stimulating effect is stronger and more immediate than other GHRP-family peptides, which some users regard as a dosing/timing consideration (for example, dosing away from planned mealtimes), though this is anecdotal practice rather than a validated protocol.

Side effects, risks, and limitations

The most consistently reported effect of GHRP-6, in both early human pharmacology research and community use, is a pronounced increase in appetite/hunger. Other effects reported in the pharmacology literature for GHSR agonists as a class include transient flushing, mild water retention, and dose-dependent increases in cortisol and prolactin at higher exposures. Long-term safety data from repeated, unsupervised self-administration has not been established in controlled human research, because GHRP-6 has not been studied that way in a formal, extended clinical trial. As with any unregulated peptide sold through research-chemical channels, additional risks unrelated to the molecule’s own pharmacology apply: unverified purity, unverified concentration, contamination, and unsterile compounding are recognized general risks with unregulated injectable peptides and have not been evaluated for any specific vendor supply of GHRP-6.

Regulatory and developmental status

GHRP-6 has never been approved as a drug for any indication in any major jurisdiction, including the United States, the European Union, or Japan. It was an important early research tool in the discovery of the growth hormone secretagogue receptor pathway but was not carried into drug development or marketing. It is not legally sold in the United States as an approved drug or dietary supplement; material sold as “GHRP-6” through research-chemical vendors is unapproved and not regulated for human use.

Frequently asked questions

What is GHRP-6?

GHRP-6 is a synthetic six-amino-acid peptide, one of the original growth hormone releasing peptides, that stimulates growth hormone release by activating the ghrelin receptor (GHSR). It also strongly stimulates appetite.

How does GHRP-6 work?

It activates the same receptor the natural hormone ghrelin uses, causing the pituitary gland to release a pulse of growth hormone. This is a separate pathway from GHRH, which is why GHRP-6 is often combined with a GHRH-type peptide in research and community protocols.

What dosage has been studied in humans?

GHRP-6 was tested in early human pharmacology studies in the late 1980s and early 1990s, including oral and injected administration, but this session could not independently verify the exact milligram/microgram doses used in those specific published studies.

What dosage commonly circulates online?

Vendor and forum sources widely describe roughly 100 to 300 micrograms per subcutaneous injection, two to three times daily. This figure is widely repeated but its original source could not be verified.

Why does GHRP-6 cause hunger?

It activates the ghrelin receptor, the same receptor that produces the natural “hunger hormone” signal, so appetite stimulation is a direct and well-documented consequence of its mechanism rather than an unrelated side effect.

Has GHRP-6 been studied in humans?

Yes, in small pharmacology studies dating back to the 1980s and 1990s that helped establish the growth hormone secretagogue receptor pathway. It has not been studied or approved as a treatment for muscle gain, fat loss, or anti-aging use.

What side effects have been reported?

A strong increase in appetite is the most consistently reported effect. Flushing, water retention, and dose-dependent increases in cortisol and prolactin have also been reported for GHSR agonists as a class. Long-term safety from unsupervised use has not been established.

Is GHRP-6 approved for use?

No. GHRP-6 has never been approved as a drug anywhere and is sold only as an unregulated research chemical.

What remains unknown about GHRP-6?

The exact doses used in the foundational human pharmacology studies were not independently confirmed in this research pass, and the safety of repeated, long-term, unsupervised self-administration has not been established.

Bottom line

GHRP-6 is a real, historically important growth hormone secretagogue that helped define an entire class of peptides and, indirectly, led to the discovery of the ghrelin receptor pathway. It reliably provokes GH release and hunger in human pharmacology research. It was never developed into an approved medicine, and the dosing regimens that circulate today in bodybuilding and peptide communities are widely repeated but not traceable to a validated clinical protocol. Anyone encountering GHRP-6 should understand it as an unapproved, unregulated research chemical whose long-term safety in self-administered use has not been established.